{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T15:37:27Z","timestamp":1772120247727,"version":"3.50.1"},"reference-count":41,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,28]],"date-time":"2025-03-28T00:00:00Z","timestamp":1743120000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000864","name":"Michael J Fox Foundation for Parkinson's Research","doi-asserted-by":"publisher","award":["MJFF-022453"],"award-info":[{"award-number":["MJFF-022453"]}],"id":[{"id":"10.13039\/100000864","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010665","name":"EU Framework Programme for Research and Innovation Marie Sk\u0142odowska-Curie Actions","doi-asserted-by":"publisher","award":["892572"],"award-info":[{"award-number":["892572"]}],"id":[{"id":"10.13039\/100010665","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010661","name":"Horizon 2020 Framework Programme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010661","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003246","name":"Dutch Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003246","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.bcp.2025.116900","type":"journal-article","created":{"date-parts":[[2025,4,3]],"date-time":"2025-04-03T16:00:23Z","timestamp":1743696023000},"page":"116900","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Characterization of [3H]AZ12464237 as a high affinity, non-nucleotide antagonist radioligand for the P2Y12 receptor"],"prefix":"10.1016","volume":"237","author":[{"given":"E. Johanna L.","family":"St\u00e9en","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Efthalia-Natalia","family":"Tousiaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lee","family":"Kingston","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Berend","family":"van der Wildt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nikolett","family":"L\u00e9n\u00e1rt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wissam","family":"Beaino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariska","family":"Verlaan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara","family":"Zarzycka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bastian","family":"Zinnhardt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u00c1d\u00e1m","family":"D\u00e9nes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luca","family":"Gobbi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iwan J.P.","family":"de Esch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charles S.","family":"Elmore","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Albert D.","family":"Windhorst","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Honer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rob","family":"Leurs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.bcp.2025.116900_b0005","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1124\/pr.58.3.3","article-title":"International union of pharmacology LVIII: update on the P2Y G protein-coupled nucleotide receptors: from molecular mechanisms and pathophysiology to therapy","volume":"58","author":"Abbracchio","year":"2006","journal-title":"Pharmacol. Rev."},{"issue":"13\u201314","key":"10.1016\/j.bcp.2025.116900_b0010","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/j.drudis.2010.05.011","article-title":"P2Y nucleotide receptors: promise of therapeutic applications","volume":"15","author":"Jacobson","year":"2010","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.bcp.2025.116900_b0015","article-title":"Molecular pharmacology of P2Y receptor subtypes","volume":"187","author":"von K\u00fcgelgen","year":"2020","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.bcp.2025.116900_b0020","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.neuropharm.2015.10.030","article-title":"Pharmacology and structure of P2Y receptors","volume":"104","author":"Von K\u00fcgelgen","year":"2016","journal-title":"Neuropharmacology"},{"issue":"7498","key":"10.1016\/j.bcp.2025.116900_b0025","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1038\/nature13083","article-title":"Structure of the human P2Y12 receptor in complex with an antithrombotic drug","volume":"508","author":"Zhang","year":"2014","journal-title":"Nature"},{"issue":"7498","key":"10.1016\/j.bcp.2025.116900_b0030","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1038\/nature13288","article-title":"Agonist-bound structure of the human P2Y12 receptor","volume":"508","author":"Zhang","year":"2014","journal-title":"Nature"},{"issue":"8","key":"10.1016\/j.bcp.2025.116900_b0035","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1007\/s10822-015-9858-z","article-title":"Modeling ligand recognition at the P2Y12 receptor in light of X-ray structural information","volume":"29","author":"Paoletta","year":"2015","journal-title":"J. Comput. Aided. Mol. Des."},{"key":"10.1016\/j.bcp.2025.116900_b0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2022.115291","article-title":"Inverse agonist efficacy of selatogrel blunts constitutive P2Y12 receptor signaling by inducing the inactive receptor conformation","volume":"206","author":"Pons","year":"2022","journal-title":"Biochem. Pharmacol."},{"issue":"5","key":"10.1016\/j.bcp.2025.116900_b0045","first-page":"382","article-title":"Structural insights into signal transduction of the purinergic receptors P2Y1R and P2Y12R","volume":"14","author":"Li","year":"2022","journal-title":"Protein Cell"},{"issue":"3","key":"10.1016\/j.bcp.2025.116900_b0050","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1002\/glia.10293","article-title":"Selective expression of Gi\/o-coupled ATP receptor P2Y12 in microglia in rat brain","volume":"44","author":"Sasaki","year":"2003","journal-title":"Glia"},{"issue":"12","key":"10.1016\/j.bcp.2025.116900_b0055","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1038\/nn1805","article-title":"The P2Y12 receptor regulates microglial activation by extracellular nucleotides","volume":"9","author":"Haynes","year":"2006","journal-title":"Nat. Neurosci."},{"issue":"1391","key":"10.1016\/j.bcp.2025.116900_b0060","first-page":"1","article-title":"P2Y12 inhibition beyond thrombosis: effects on inflammation","volume":"21","author":"Mansour","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.bcp.2025.116900_b0065","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/nn.3599","article-title":"Identification of a unique TGF-\u03b2-dependent molecular and functional signature in Microglia","volume":"17","author":"Butovsky","year":"2014","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.bcp.2025.116900_b0070","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1146\/annurev-immunol-051116-052358","article-title":"Microglia function in the central nervous system during health and neurodegeneration","volume":"35","author":"Colonna","year":"2017","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.bcp.2025.116900_b0075","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1186\/s12974-017-1034-z","article-title":"Purinergic receptors P2Y12R and P2X7R: potential targets for PET imaging of microglia phenotypes in multiple sclerosis","volume":"14","author":"Beaino","year":"2017","journal-title":"J. Neuroinflammation."},{"issue":"3","key":"10.1016\/j.bcp.2025.116900_b0080","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/molecules23030607","article-title":"PET imaging of microglial activation - beyond targeting TSPO","volume":"23","author":"Janssen","year":"2018","journal-title":"Molecules"},{"key":"10.1016\/j.bcp.2025.116900_b0085","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2022.128837","article-title":"Strategies for targeting the P2Y12 receptor in the central nervous system","volume":"71","author":"Ma","year":"2022","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.bcp.2025.116900_b0090","unstructured":"I. Kirk. New Assay. Patent application WO 00\/33080, June 8 2000."},{"issue":"9","key":"10.1016\/j.bcp.2025.116900_b0095","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1111\/j.1538-7836.2009.03527.x","article-title":"Ticagrelor binds to human P2Y12 independently from ADP but antagonizes ADP\u2010induced receptor signaling and platelet aggregation","volume":"7","author":"van Giezen","year":"2009","journal-title":"J. Thromb. Haemost."},{"issue":"3","key":"10.1016\/j.bcp.2025.116900_b0100","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1172\/JCI110786","article-title":"2-methylthioadenosine[\u03b2-32P]diphosphate. An agonist and radioligand for the receptor that inhibits the accumulation of cyclic AMP in intact blood platelets","volume":"71","author":"Macfarlane","year":"1983","journal-title":"J. Clin. Invest."},{"issue":"24","key":"10.1016\/j.bcp.2025.116900_b0105","doi-asserted-by":"crossref","first-page":"5450","DOI":"10.1016\/j.bmcl.2005.08.104","article-title":"Synthesis and preliminary evaluation of [3H]PSB-0413, a selective antagonist radioligand for platelet P2Y12 receptors","volume":"15","author":"El-Tayeb","year":"2005","journal-title":"Bioorganic Med. Chem. Lett."},{"issue":"10","key":"10.1016\/j.bcp.2025.116900_b0110","doi-asserted-by":"crossref","first-page":"2877","DOI":"10.1016\/j.bmcl.2011.03.088","article-title":"A novel series of piperazinyl-pyridine ureas as antagonists of the purinergic P2Y12 receptor","volume":"21","author":"Bach","year":"2011","journal-title":"Bioorganic Med. Chem. Lett."},{"key":"10.1016\/j.bcp.2025.116900_b0115","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.ejmech.2013.04.007","article-title":"Synthesis, structure-property relationships and pharmacokinetic evaluation of ethyl 6-aminonicotinate sulfonylureas as antagonists of the P2Y12 receptor","volume":"65","author":"Bach","year":"2013","journal-title":"Eur. J. Med. Chem."},{"issue":"19","key":"10.1016\/j.bcp.2025.116900_b0120","doi-asserted-by":"crossref","first-page":"5400","DOI":"10.7150\/thno.25572","article-title":"Identification of new molecular targets for PET imaging of the microglial anti-inflammatory activation state","volume":"8","author":"Villa","year":"2018","journal-title":"Theranostics"},{"issue":"23","key":"10.1016\/j.bcp.2025.116900_b0125","doi-asserted-by":"crossref","first-page":"4465","DOI":"10.1021\/acschemneuro.1c00641","article-title":"Novel thienopyrimidine-based PET tracers for P2Y 12 receptor imaging in the brain","volume":"12","author":"van der Wildt","year":"2021","journal-title":"ACS Chem. Neurosci."},{"issue":"15","key":"10.1016\/j.bcp.2025.116900_b0130","doi-asserted-by":"crossref","first-page":"5778","DOI":"10.1021\/jo070831o","article-title":"An algorithm for the deconvolution of mass spectrosopic patterns in isotope labeling studies. evaluation for the hydrogen-deuterium exchange reaction in ketones","volume":"72","author":"Gruber","year":"2007","journal-title":"J. Org. Chem."},{"issue":"11","key":"10.1016\/j.bcp.2025.116900_b0135","doi-asserted-by":"crossref","first-page":"2374","DOI":"10.1021\/acschemneuro.7b00272","article-title":"Pharmacological evaluation of novel bioisosteres of an adamantanyl benzamide P2X 7 receptor antagonist","volume":"8","author":"Wilkinson","year":"2017","journal-title":"ACS Chem. Neurosci."},{"issue":"3","key":"10.1016\/j.bcp.2025.116900_b0140","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20211071","article-title":"Microglia modulate blood flow, neurovascular coupling, and hypoperfusion via purinergic actions","volume":"219","author":"Cs\u00e1sz\u00e1r","year":"2022","journal-title":"J. Exp. Med."},{"issue":"17","key":"10.1016\/j.bcp.2025.116900_b0145","doi-asserted-by":"crossref","first-page":"7015","DOI":"10.1021\/jm400820m","article-title":"Lead optimization of ethyl 6-aminonicotinate acyl sulfonamides as antagonists of the P2Y12 receptor. separation of the antithrombotic effect and bleeding for candidate Drug AZD1283","volume":"56","author":"Bach","year":"2013","journal-title":"J. Med. Chem."},{"issue":"20","key":"10.1016\/j.bcp.2025.116900_b0150","doi-asserted-by":"crossref","first-page":"8615","DOI":"10.1021\/jm300771j","article-title":"Identification of high-affinity P2Y 12 antagonists based on a phenylpyrazole glutamic acid piperazine backbone","volume":"55","author":"Zech","year":"2012","journal-title":"J. Med. Chem."},{"issue":"12","key":"10.1016\/j.bcp.2025.116900_b0155","doi-asserted-by":"crossref","first-page":"3784","DOI":"10.1021\/jm9003297","article-title":"High-affinity, non-nucleotide-derived competitive antagonists of platelet P2Y 12 receptors","volume":"52","author":"Baqi","year":"2009","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bcp.2025.116900_b0160","doi-asserted-by":"crossref","first-page":"6013","DOI":"10.1016\/j.bmcl.2007.07.057","article-title":"From ATP to AZD6140: the discovery of an orally active reversible P2Y12 receptor antagonist for the prevention of thrombosis","author":"Springthorpe","year":"2007","journal-title":"Bioorganic Med. Chem. Lett."},{"issue":"2","key":"10.1016\/j.bcp.2025.116900_b0165","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.bcp.2005.04.021","article-title":"Synthesis of pyridoxal phosphate derivatives with antagonist activity at the P2Y13 receptor","volume":"70","author":"Kim","year":"2005","journal-title":"Biochem. Pharmacol."},{"issue":"1","key":"10.1016\/j.bcp.2025.116900_b0170","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1124\/mol.113.085654","article-title":"A selective high-affinity antagonist of the P2Y 14 receptor inhibits UDP-glucose\u2013stimulated chemotaxis of human neutrophils","volume":"84","author":"Barrett","year":"2013","journal-title":"Mol. Pharmacol."},{"issue":"June","key":"10.1016\/j.bcp.2025.116900_b0175","article-title":"Safety screening in early drug discovery: an optimized assay panel","volume":"99","author":"Bendels","year":"2019","journal-title":"J. Pharmacol. Toxicol. Methods"},{"issue":"1","key":"10.1016\/j.bcp.2025.116900_b0180","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-018-24814-0","article-title":"Identification of the allosteric P2X7 receptor antagonist [11C]SMW139 as a PET tracer of microglial activation","volume":"8","author":"Janssen","year":"2018","journal-title":"Sci. Rep."},{"issue":"11","key":"10.1016\/j.bcp.2025.116900_b0185","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1111\/jth.12719","article-title":"Competitive mode and site of interaction of ticagrelor at the human platelet P2Y12-receptor","volume":"12","author":"Hoffmann","year":"2014","journal-title":"J. Thromb. Haemost."},{"issue":"9","key":"10.1016\/j.bcp.2025.116900_b0190","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1016\/j.bcp.2004.01.011","article-title":"Diisothiocyanate derivatives as potent, insurmountable antagonists of P2Y6 nucleotide receptors","volume":"67","author":"Mamedova","year":"2004","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.bcp.2025.116900_b0195","unstructured":"Amino acid homology was determined by pairwise sequence alignment in ICM-Pro (Version 3.9-1c, Molsoft L.L.C., La Jolla, USA) using the Zero End-gap Global Alignment (ZEGA) algorithm (reference 40) with default settings. UniProt codes: Q9H244 (hP2Y12R), Q9EPX4 (rP2Y12R) and Q9CPV9 (mP2Y12R)."},{"issue":"1","key":"10.1016\/j.bcp.2025.116900_b0200","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1006\/jmbi.1997.1287","article-title":"Do aligned sequences share the same fold?","volume":"273","author":"Abagyan","year":"1997","journal-title":"J. Mol. Biol."},{"issue":"1","key":"10.1016\/j.bcp.2025.116900_b0205","article-title":"G protein-coupled receptors: structure- and function-based drug discovery","volume":"6","author":"Yang","year":"2021","journal-title":"Signal Transduct. Target. Ther."}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295225001625?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295225001625?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T15:24:57Z","timestamp":1762097097000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295225001625"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":41,"alternative-id":["S0006295225001625"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2025.116900","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2024.10.10.617599","asserted-by":"object"}]},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Characterization of [3H]AZ12464237 as a high affinity, non-nucleotide antagonist radioligand for the P2Y12 receptor","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2025.116900","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"116900"}}